Advertisement Pharmaceutical Business review - Page 14 of 5293 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 12, 2026

FDA approves Asahi Kasei’s Hovilpri for refractory HSV

The US Food and Drug Administration (FDA) has approved Asahi Kasei Therapeutics’ Hovilpri (pritelivir) 100mg tablets to treat refractory mucocutaneous herpes simplex virus (HSV) lesions in immunocompromised adults.

Asahi Kasei Therapeutics is the global specialty pharmaceutical unit of Tokyo’s Asahi Kasei. Credit: Asahi Kasei Therapeutics/Business Wire.